NCT04506086 2025-05-18
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 4 Terminated
Clinical Trials
7 trialsNCT00198991 2022-08-18
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
Goethe University
Phase 4 Completed
NCT05137860 2022-01-18
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
Hospital General de Mexico
Phase 4 Unknown
NCT02314871 2019-03-13
Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery
The Institute of Molecular and Translational Medicine, Czech Republic
Phase 4 Completed
NCT01347996 2017-11-29
Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
Cytovia, Inc.
Phase 4 Completed
NCT00526175 2016-01-20
LAL-BR/2001: Study Treatment to Low Risk ALL
PETHEMA Foundation
Phase 4 Completed
NCT00199004 2010-08-23
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
Johann Wolfgang Goethe University Hospital
Phase 4 Completed